Vanda Pharmaceuticals (VNDA) Aktievy
Vanda Pharmaceuticals Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling och kommersialisering av behandlingar för att tillgodose stora medicinska behov världen över. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
VNDA Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vanda Pharmaceuticals Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$5.38 |
| 52 veckors högsta | US$9.94 |
| 52 veckors lägsta | US$4.27 |
| Beta | 0.64 |
| 1 månads förändring | -1.82% |
| 3 månaders förändring | -13.09% |
| 1 års förändring | 19.29% |
| 3 års förändring | -5.78% |
| 5 års förändring | -67.65% |
| Förändring sedan börsintroduktionen | -44.42% |
Senaste nyheter och uppdateringar
Analysartikel • Aug 08
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price
It's shaping up to be a tough period for Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ), which a week ago released some...
Uppdatering av berättelse • Aug 07
VNDA: Rare Disease Pipeline Will Drive Future Psychiatry And Vomiting Prospects
Analysts have trimmed their fair value estimate for Vanda Pharmaceuticals by $1.75 to $5.75. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples following the latest Street research.Recent updates
Analysartikel • Aug 08
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price
It's shaping up to be a tough period for Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ), which a week ago released some...Uppdatering av berättelse • Aug 07
VNDA: Rare Disease Pipeline Will Drive Future Psychiatry And Vomiting Prospects
Analysts have trimmed their fair value estimate for Vanda Pharmaceuticals by $1.75 to $5.75. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples following the latest Street research.Seeking Alpha • Jul 17
Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold
Summary Vanda Pharmaceuticals is downgraded to hold due to mounting losses, cash burn, and uncertain pipeline execution. Fanapt revenues are growing, but looming patent expiry and Hetlioz decline threaten near-term revenue stability. Bysanti and Nereus offer potential upside, yet commercial traction and clinical milestones remain unproven and delayed. VNDA’s cash could be depleted by the end of 2027; multiple pipeline bets heighten both risk and opportunity, demanding cautious positioning. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 01
VNDA: Motion Sickness Launch And GLP 1 Vomiting Data Will Drive 2026 Outlook
The analyst price target for Vanda Pharmaceuticals has been reduced by $3 to $21, as analysts reassess fair value and key model inputs including discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Bullish analysts covering Vanda Pharmaceuticals acknowledge the reduced price target, but still highlight areas where they see the company’s valuation as supported by underlying assumptions and potential execution on its pipeline and commercial strategy.Uppdatering av berättelse • Jun 17
VNDA: Psychiatry Franchise And Motion Vomiting Opportunity Will Drive Future Prospects
Analysts have trimmed their price target on Vanda Pharmaceuticals stock by $3, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels that modestly adjust the risk and return profile built into their models. Analyst Commentary on Vanda Pharmaceuticals Recent commentary around Vanda Pharmaceuticals reflects a more cautious tone, with bearish analysts adjusting assumptions that feed directly into valuation models for the stock.Uppdatering av berättelse • Jun 02
VNDA: Psychiatry Franchise And GLP 1 Vomiting Opportunity Will Drive Future Prospects
Narrative Update: Vanda Pharmaceuticals Analyst Price Target Shift The Street's view on Vanda Pharmaceuticals has adjusted, with one firm cutting its price target by $3. Analysts point to existing commercial sales of about $200M, an updated Fanapt launch with different economics, and potential Nereus use in GLP-1 related vomiting as key factors behind the revised targets.
Uppdatering av berättelse • May 17
VNDA: Psychiatry Franchise And New Launches Will Drive Earnings Repricing
Analysts have adjusted the fair value estimate for Vanda Pharmaceuticals to $14.90 from $12.67, reflecting updated expectations for profitability, P/E assumptions, and the potential contribution from BYSANTI and other near-commercial assets highlighted in recent research. Analyst Commentary Recent Street research on Vanda Pharmaceuticals presents a mixed picture, with some analysts emphasizing upside from newly approved and near-commercial assets, while others are trimming targets as expectations and assumptions are recalibrated.Uppdatering av berättelse • Apr 28
VNDA: Psychiatry Franchise And Nereus Data Will Shape Balanced Future Prospects
Analysts have raised their average price target on Vanda Pharmaceuticals by $3, from $14 to $17, citing updated revenue models after BYSANTI's approval, expectations for growth in the psychiatry franchise, and potential upside from additional commercial and near-commercial assets. Analyst Commentary Recent research has highlighted a more constructive tone around Vanda Pharmaceuticals, with multiple firms publishing views that anchor on BYSANTI, the broader psychiatry franchise, and the company’s commercial portfolio.Uppdatering av berättelse • Apr 14
VNDA: Psychiatry Franchise And Nereus Opportunity Will Shape Balanced Future Upside
Analysts have raised their average price target for Vanda Pharmaceuticals to reflect updated expectations around the recently approved BYSANTI, ongoing prescriptions for Fanapt, and potential upside from Nereus in GLP-1 related vomiting, with current targets from recent research ranging from $17 to $24. Analyst Commentary Recent research has generally been constructive on Vanda Pharmaceuticals, with several firms assigning Buy ratings alongside price targets in the mid to high teens and low twenties.Uppdatering av berättelse • Mar 31
VNDA: Psychiatry Franchise And GLP 1 Vomiting Opportunity Will Shape 2026 Outlook
Analysts have raised their fair value estimate for Vanda Pharmaceuticals to $24 from $22, reflecting updated models that incorporate the FDA approval of Bysanti, higher expectations for the psychiatry franchise, and emerging opportunities such as Nereus in GLP-1 related vomiting. Analyst Commentary Bullish analysts are leaning into Vanda's updated story around Bysanti, Fanapt, and newer assets, with several raising fair value assumptions and highlighting a broader psychiatry and gastrointestinal opportunity set.Uppdatering av berättelse • Mar 16
VNDA: Psychiatry Reliance Will Limit Upside Despite Recent Drug Approvals
Analysts have raised their average price targets for Vanda Pharmaceuticals into the mid to high teens in dollar terms, citing the recent FDA approval of Bysanti, updated revenue models for the psychiatry franchise, and potential upside from the Nereus program as key reasons for the change. Analyst Commentary Recent Street research around Vanda Pharmaceuticals has centered on the implications of Bysanti's FDA approval, the outlook for the psychiatry franchise, and the potential contribution of pipeline assets such as Nereus and tasimelteon.Uppdatering av berättelse • Mar 02
VNDA: Psychiatry Concentration Risk Will Drive A Cautious Forward Outlook
Analysts have lifted their average price target for Vanda Pharmaceuticals to a higher range of $17 to $24, citing updated revenue models that now include expected BYSANTI contributions and revised assumptions for its psychiatry franchise. Analyst Commentary Recent research has centered on the impact of BYSANTI and the broader psychiatry franchise on Vanda Pharmaceuticals, with updated revenue models now reflecting expected BYSANTI contributions and revised assumptions around prescription trends.Uppdatering av berättelse • Feb 16
VNDA: Jet Lag Setback Will Keep Focus On 2026 Earnings Outlook
Analysts kept their $22 price target for Vanda Pharmaceuticals unchanged, citing recent FDA feedback on tasimelteon for jet lag as a limited setback that was already excluded from their valuation assumptions. Analyst Commentary Bullish analysts frame the recent FDA feedback on tasimelteon for jet lag as a contained issue.Uppdatering av berättelse • Feb 02
VNDA: Jet Lag Setback Will Keep Focus On Imsidolimab BLA Milestone
Analysts have lifted their fair value estimate for Vanda Pharmaceuticals to $22 from $20, citing Street research that views the recent FDA decision on tasimelteon for jet lag as a limited setback that was not factored into prior valuation work. Analyst Commentary Bullish analysts frame the FDA decision on tasimelteon for jet lag as a limited setback rather than a thesis changer for Vanda Pharmaceuticals.Uppdatering av berättelse • Jan 19
VNDA: Imsidolimab Filing And Motion Sickness Approval Will Shape Balanced Outlook
Analysts have kept their fair value estimate for Vanda Pharmaceuticals steady at US$7.50, while modestly updating assumptions for the discount rate, revenue growth, profit margin, and future P/E after viewing the recent tasimelteon sNDA setback as a limited issue that was not central to their prior price target work. Analyst Commentary Street research commentary around Vanda Pharmaceuticals has framed the recent tasimelteon update as a limited issue for the equity story, with some firms explicitly stating that their valuation work did not depend on jet lag revenues for HETLIOZ.Uppdatering av berättelse • Jan 04
VNDA: Imsidolimab Milestones And Motion Sickness Launch Will Drive Balanced Outlook
Analysts have modestly raised their fair value estimate for Vanda Pharmaceuticals to approximately $7.50 from about $5.00 per share, citing improving milestone visibility tied to the anticipated imsidolimab BLA submission and a reassessment of long term earnings potential, even as revenue growth assumptions have become more tempered. Analyst Commentary Bearish analysts acknowledge that the clearer path toward an imsidolimab BLA filing has improved Vanda's long term earnings visibility, but they remain wary that the ultimate revenue contribution could fall short of current expectations.
Ny berättelse • Apr 24
New Indications And Pipeline Advances Will Strengthen Position
Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.Seeking Alpha • Sep 05
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Summary Fanapt, approved for bipolar I disorder, faces significant competition from generics like Abilify, making it unlikely to drive substantial revenue growth. Ponvory, acquired from Janssen, faces similar competitive pressures, with generic versions of similar drugs dominating the multiple sclerosis market. Despite failing its primary endpoint in gastroparesis, Vanda is still pushing for regulatory approval for tradipitant, facing regulatory hurdles. Despite receiving two acquisition offers with a premium, Vanda rejected them, raising concerns about their cash management and future stock performance. Vanda's stock remains a hold due to cash strength, but limited product pipeline differentiation makes long-term growth prospects challenging. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Summary Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill. Retail shareholders can buy Vanda for less than the company's cash value, getting the potential benefit from the actions of activist shareholders for free. Read the full article on Seeking AlphaSeeking Alpha • Jun 18
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Summary Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA’s upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA’s undervaluation and strategic value. VNDA trades below its cash value, with significant cash reserves and no debt, suggesting financial stability and growth potential. VNDA's diversified late-stage IP and substantial TAM make it a compelling investment despite the biotech and M&A risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Summary Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not significantly contribute to Vanda's bottom line as there are already several drugs approved for this indication. Despite a strong balance sheet, Vanda's future is heavily reliant on expanding existing drugs indications and new drug successes. Maintain "Hold" recommendation: Fanapt's bipolar indication is unlikely to significantly impact revenue; the company faces moderate-to-high risk. Read the full article on Seeking AlphaAnalysartikel • Feb 15
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) stock, leading do a rise in the share price...Seeking Alpha • Feb 13
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Summary Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has operational assets beyond its cash. The market's current valuation of VNDA appears too pessimistic and a range of $5-10/share may be more reasonable, even assuming imperfect capital allocation. There could be further upside if drug approvals and operational performance go well in 2024. If things trend poorly, a valuation below $4/share is possible if operational performance is weak in 2024 and FDA approvals are not forthcoming. Read the full article on Seeking AlphaAnalysartikel • Feb 10
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong...Aktieägarnas avkastning
| VNDA | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 7.0% | 5.2% | -2.1% |
| 1Y | 19.3% | 43.5% | 18.8% |
Avkastning vs industri: VNDA presterade sämre än US Biotechs branschen som gav 43.5 % under det senaste året.
Avkastning vs Marknaden: VNDA presterade sämre än US marknaden som gav 18.8 % under det senaste året.
Prisvolatilitet
| VNDA volatility | |
|---|---|
| VNDA Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: VNDA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: VNDA s veckovolatilitet har minskat från 12% till 6% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2002 | 533 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling och kommersialisering av behandlingar för att tillgodose stora medicinska behov världen över. Bolagets kommersiella portfölj omfattar Fanapt för akut behandling av maniska eller blandade episoder i samband med bipolär I-sjukdom och behandling av schizofreni; HETLIOZ för behandling av sömnstörningar som inte omfattar 24 timmar och nattsömnstörningar; PONVORY för behandling av skovvis förlöpande former av multipel skleros; och NEREUSTM för förebyggande av rörelseutlösta kräkningar. Företaget utvecklar också Fanapt (iloperidon), en långtidsverkande injicerbar formulering för behandling av schizofreni och högt blodtryck; BysantiTM (milsaperidon), för akut behandling av maniska eller blandade episoder i samband med bipolär I-störning, och för behandling av schizofreni och egentlig depression; HETLIOZ (tasimelteon) för behandling av jetlag, insomni, pediatrisk insomni, fördröjd sömnfasstörning och pediatrisk Non-24, PONVORY (ponesimod) för behandling av psoriasis och ulcerös kolit samt NEREUSTM (tradipitant) för förebyggande av kräkningar som framkallas av GLP-1-receptoragonister samt för behandling av gastropares och atopisk dermatit.
Vanda Pharmaceuticals Inc. Sammanfattning av grunderna
| VNDA grundläggande statistik | |
|---|---|
| Börsvärde | US$336.78m |
| Vinst(TTM) | -US$274.85m |
| Intäkter(TTM) | US$215.72m |
1.5x
P/S-förhållande-1.2x
P/E-förhållandeÄr VNDA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| VNDA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$215.72m |
| Kostnad för intäkter | US$13.51m |
| Bruttovinst | US$202.22m |
| Övriga kostnader | US$477.07m |
| Intäkter | -US$274.85m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -4.55 |
| Bruttomarginal | 93.74% |
| Nettovinstmarginal | -127.41% |
| Skuld/egenkapitalförhållande | 0% |
Hur har VNDA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 05:10 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Vanda Pharmaceuticals Inc. bevakas av 17 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |